You are here

Umbralisib (TG Therapeutics/Rhizen) Drug Overview & Product Profiles 2017-2018 & 2019-2026

DUBLIN, July 15, 2019 /PRNewswire/ -- The "umbralisib" report has been added to ResearchAndMarkets.com's offering.

Umbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform plays a role in B-cell development and function, and is often overactivated in B-cell malignancies.

Umbralisib has a unique chemical structure that confers greater specificity to target sites and may produce equivalent or improved efficacy, along with a more favorable safety profile, in comparison to other PI3K inhibitors such as Zydelig (idelalisib; Gilead) or Copiktra (duvelisib; Verastem) in non-Hodgkin's lymphoma.

Analyst Outlook

TG Therapeutics is developing its phosphoinositide 3-kinase (PI3K) inhibitor umbralisib as part of a combination with its in-house cluster of differentiation (CD)20-targeted antibody, ublituximab. The combination is being evaluated in the Phase II/III UNITY-NHL trial (ClinicalTrials.gov identifier: NCT02793583) for the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL) patients, including diffuse large B-cell lymphoma (DLBCL) patients.

The combination has demonstrated early signs of efficacy, but significant adverse events potentially tied to PI3K inhibition, such as neutropenia, remain a concern. As such, umbralisib's uptake may be limited by its side-effect profile, the potentially high cost of a combination regimen with ublituximab, and strong forecasted competition from approved regimens and several late-phase competitors targeting the relapsed or refractory patient segment.

Key Topics Covered:

OVERVIEW
Drug Overview
Product Profiles
umbralisib : NHL: Follicular lymphoma (FL)
umbralisib : NHL: Diffuse large B-cell lymphoma (DLBCL)

LIST OF FIGURES
Figure 1: Umbralisib for follicular lymphoma - SWOT analysis
Figure 2: The authors drug assessment summary of umbralisib for follicular lymphoma
Figure 3: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country, 2017-26
Figure 4: Umbralisib for diffuse large B-cell lymphoma - SWOT analysis
Figure 5: The authors drug assessment summary for umbralisib in diffuse large B-cell lymphoma
Figure 6: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017-26

LIST OF TABLES
Table 1: Umbralisib drug profile
Table 2: Umbralisib ongoing pivotal trials in follicular lymphoma
Table 3: Umbralisib clinical trial data in follicular lymphoma
Table 4: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017-26
Table 5: Umbralisib drug profile
Table 6: Umbralisib ongoing pivotal trial in diffuse large B-cell lymphoma
Table 7: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/j9r709

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Cision View original content:http://www.prnewswire.com/news-releases/umbralisib-tg-therapeuticsrhizen-drug-overview--product-profiles-2017-2018--2019-2026-300884836.html

SOURCE Research and Markets